



PRESS RELEASE

Collectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences

New York, August 26, 2015 – Collectis (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured during several conferences in the coming weeks.

The Immunotherapy and Vaccine Summit

August 24th to 28th, 2015, Boston, USA

- **André Choulika, Ph.D., Chairman and CEO of Collectis, will be presenting in the panel "Advantages and Disadvantages of Different Gene Editing Technologies"** on Thursday, August 27th at 11:45AM.
- **Dr Choulika will also give a presentation entitled "Allogeneic Universal CAR-T Cells Engineered With TALEN®"** during the session "Merging Gene Editing and Immunotherapy" on Thursday, August 27th at 3:05PM.
- **Julien Valton, Ph.D., Senior Scientist at Collectis, will give a presentation entitled "A Multidrug Resistant Engineered CAR T-Cell for Allogeneic Combination Immunotherapy"** during the session "Chimeric Antigen Receptors" on Thursday, August 27th at 11:15AM.

CRI-CIMT-EATI-AACR Immunotherapy Conference

September 16th to 19th, 2015, New York, USA

- **Laurent Poirot, Head of Early Discovery at Collectis, to present a poster entitled "Targeted genome modifications for Improved Adoptive Immunotherapy"** on Wednesday, September 16.
- **Philippe Duchateau, Chief Scientific Officer at Collectis, to present a poster entitled "Design of a chimeric antigen receptor (CAR) with controllable function via small molecule"** on Friday, September 18.
- **Julianne Smith, VP CAR T Development at Collectis, to present a poster entitled "Allogeneic CAR T-cells for Adoptive Immunotherapy"** on Friday, September 18.

Phacilitate Cell & Gene Therapy

September 29th to 30th, 2015, Barcelona, Spain

- **Stéphan Reynier, Chief Regulatory and Compliance Officer at Collectis, to present as a chairperson during the session: "What is the most realistic, practicable supply chain solution for this particular class of products in Europe? What would be most feasible for rare vs. common indications?"** This roundtable discussion will take place on Wednesday, September 30th, from 4:20 to 5:30PM.

About Collectis

Collectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

TALEN® is a registered trademark owned by the Collectis Group.

For further information, please contact:**Media contacts**

Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@collectis.com

Caitlin Kasunich / Dixon Moretz
KCSA Strategic Communications
212.896.1241 / 212.896.1251
ckasunich@kcsa.com / dmoretz@kcsa.com

For investor relations (IR) matters:

Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@collectis.com